A Case of Lung Mucoepidermoid Carcinoma with EGFR Mutation Successfully Treated by Gefitinib

DOI Web Site 2 Citations 11 References
  • Tamaki Takeshi
    Department of Respiratory Medicine, Kansai Medical University Hirakata Hospital
  • Tanijiri Tsutomu
    Department of Respiratory Medicine, Kansai Medical University Hirakata Hospital
  • Katashiba Yuichi
    Department of Respiratory Medicine, Kansai Medical University Hirakata Hospital
  • Imamura Maiko
    Department of Respiratory Medicine, Kansai Medical University Hirakata Hospital
  • Yonezu Seibun
    Department of Respiratory Medicine, Kansai Medical University Hirakata Hospital
  • Fukuhara Shirou
    Department of Respiratory Medicine, Kansai Medical University Hirakata Hospital

Bibliographic Information

Other Title
  • ゲフィチニブにより奏効をみたＥＧＦＲ遺伝子変異を伴う肺粘表皮癌の１例

Search this article

Description

Background. Pulmonary or bronchial mucoepidermoid carcinoma is a rare subtype of lung cancer, and effective treatment has not yet been established for advanced stage cases. Case. A 41-year-old man with headache and back pain was referred to our hospital because biopsy of a right lower jaw tumor had revealed metastatic carcinoma, and computed tomography revealed a right hilar tumor. In our hospital, fiberoptic bronchoscopy showed stricture of the right middle lobe bronchus and sessile polypoid tumor, and a biopsy specimen revealed high-grade mucoepidermoid carcinoma. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) showed abnormal accumulations in the mediastinal lymph node, and liver, bone, skin and muscular lesions. Multiple metastasis was suspected, and it was classified stage IV (cT1N2M1). After receiving chemotherapy with carboplatin and paclitaxel, the metastatic liver and bone lesions worsened. Gefitinib was administered as a second-line therapy, resulting in a partial response. Molecular screening of the tumor identified an EGFR exon 19 deletion mutation. Conclusion. There is sometimes an EGFR mutation among cases of mucoepidermoid carcinoma. This case suggests that EGFR tyrosine kinase inhibitors could be effective for the treatment of mucoepidermoid carcinoma with EGFR mutation.<br>

Journal

  • Haigan

    Haigan 50 (1), 27-32, 2010

    The Japan Lung Cancer Society

Citations (2)*help

See more

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top